Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $1.8 million.

  • Editas Medicine's Interest & Investment Income fell 4813.03% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year decrease of 5638.5%. This contributed to the annual value of $14.1 million for FY2024, which is 1994.76% down from last year.
  • As of Q3 2025, Editas Medicine's Interest & Investment Income stood at $1.8 million, which was down 4813.03% from $2.1 million recorded in Q2 2025.
  • Editas Medicine's Interest & Investment Income's 5-year high stood at $5.1 million during Q3 2023, with a 5-year trough of $134000.0 in Q1 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $2.1 million (2025), whereas its average is $2.3 million.
  • In the last 5 years, Editas Medicine's Interest & Investment Income crashed by 9140.47% in 2021 and then skyrocketed by 144971.43% in 2022.
  • Over the past 5 years, Editas Medicine's Interest & Investment Income (Quarter) stood at $175000.0 in 2021, then soared by 1449.71% to $2.7 million in 2022, then soared by 88.13% to $5.1 million in 2023, then plummeted by 76.46% to $1.2 million in 2024, then surged by 52.46% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $2.1 million for Q2 2025, and $2.7 million during Q1 2025.